Pyxis Oncology, Inc. (PYXS)

NASDAQ: PYXS · IEX Real-Time Price · USD
-0.04 (-2.58%)
At close: Nov 28, 2023, 4:00 PM
-0.03 (-1.99%)
After-hours: Nov 28, 2023, 4:42 PM EST

Company Description

Pyxis Oncology, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies to treat cancers.

Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody, which is in Phase 1 clinical trial for the treatment of solid tumors, including non-small cell lung cancer (NSCLC) without driver mutations/translocations, breast cancer, endometrial cancer, thyroid cancer, kidney cancer, cholangiocarcinoma, bladder cancer, colorectal cancer, and head and neck squamous cell carcinoma.

The company's antibody drug conjugate product candidate is PYX-201, an investigational human immunoglobulin G1 isotype site-specifically conjugated, which is in Phase 1 clinical trial for solid tumors, including NSCLC, hormone receptor-positive breast cancer, ovarian cancer, thyroid cancer, pancreatic ductal adenocarcinoma, soft tissue sarcoma, hepatocellular carcinoma, and kidney cancer.

The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Pyxis Oncology, Inc.
Pyxis Oncology logo
Country United States
Founded 2018
IPO Date Oct 1, 2021
Industry Biotechnology
Sector Healthcare
Employees 67
CEO Dr. Lara S. Sullivan M.D., MBA

Contact Details

321 Harrison Avenue
Boston, Massachusetts 02118
United States
Phone (617) 221-9059

Stock Details

Ticker Symbol PYXS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $16.00
CIK Code 0001782223
CUSIP Number 747324101
ISIN Number US7473241013
Employer ID 83-1160910
SIC Code 2834

Key Executives

Name Position
John L. Flavin M.B.A., MBA, Ph.D. Co-Founder and Independent Chairman
Dr. Lara S. Sullivan M.D., MBA Chief Executive Officer, President and Director
Pamela Yanchik Connealy M.B.A. Chief Financial Officer
Dr. Jay M. Feingold M.D., Ph.D. Chief Medical Officer
Jitendra Wadhane Chief Accounting Officer, Senior Vice President of Finance and Corporate Controller
Dr. Balu N. Balasubramanian Ph.D. Interim Chief Technology Officer
Dr. Jan Pinkas Ph.D. Chief Scientific Officer
Martina Molsbergen B.S. Interim Chief Business Officer
Dr. Charles T. Gombar Ph.D. Senior Vice President of Portfolio and Program Management

Latest SEC Filings

Date Type Title
Nov 28, 2023 8-K Current Report
Nov 7, 2023 10-Q Quarterly Report
Nov 7, 2023 8-K Current Report
Oct 27, 2023 8-K/A [Amend] Current report
Sep 18, 2023 144 Filing
Sep 14, 2023 144 Filing
Sep 13, 2023 144 Filing
Sep 12, 2023 144 Filing
Sep 11, 2023 144 Filing
Sep 5, 2023 144 Filing